Skip to main
ENOV

Enovis Corp (ENOV) Stock Forecast & Price Target

Enovis Corp (ENOV) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enovis is a leading medical technology manufacturer and distributor focused on orthopedic and recovery science solutions that generate better patient outcomes. With strong performance in both the Prevention & Recovery and Reconstructive segments, the company is experiencing steady above-market growth, backed by its strong portfolio of new products. Despite the 2H26 guidance being 4Q loaded, the company remains on track to deliver on its revenue and earnings targets, driven by margin expansion, improving free cash flow, and a robust pipeline of innovative products. The company's current discount to its peer group is unwarranted, and we believe shares are trading at a bargain.

Bears say

Enovis is facing major challenges in terms of organic top-line growth and profitability, which may lead to further multiple contraction and limit share performance in the face of its relatively inexpensive valuation. This is due to declining organic growth, changes in sales force structure, and decreases in profitability. There are also risks of losing market share to competitors, manufacturing risks, slower (or faster) adoption of robotics in orthopedics, and limitations on margin expansion and salesforce disruptions.

Enovis Corp (ENOV) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enovis Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enovis Corp (ENOV) Forecast

Analysts have given Enovis Corp (ENOV) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Enovis Corp (ENOV) has a Strong Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enovis Corp (ENOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.